American Express Reveals 2023 Top Travel Trends
23.3.2023 16:00:00 EET | Business Wire | Press release
American Express Travel® released their 2023 Global Travel Trends Report today, highlighting four global trends inspiring people to travel this year:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005091/en/
American Express Travel's 2023 Global Travel Trends Report
- The Rise of “Set-Jetting”: Popular movies, TV shows and social media are inspiring people to travel to places they see onscreen, like Italy, Paris, Yellowstone, and London
- Delicious Destinations: From top restaurants to local favorites to cooking classes, people are choosing their next destination based on what they’ll eat
- A Wellness Wave: Restorative vacations are on the rise as travelers prioritize self-care and mental and physical health
- Traveling Off the Beaten Path: Travelers want to discover hidden gems and support the local community when they visit
The report, based on survey data from travelers from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, found that more than half (52%) of respondents say they plan to take more trips this year than last year and 50% of respondents are planning to spend more money on travel in 2023 than 2022. 84% of Gen Z and Millennials surveyed would rather take a dream vacation than purchase a new luxury item, and 79% agree that travel is an important budget priority.
“Vacations are precious, and travelers are prioritizing personalized itineraries built around their passions, from planning an entire vacation for a single dinner reservation to getting the perfect video for TikTok,” says Audrey Hendley, President of American Express Travel. “No matter what the inspiration is, American Express Travel Consultants have the expertise to help every type of traveler plan all types of trips.”
Top insights from American Express Travel’s 2023 Global Travel Trends Report include:
-
Pop culture and social media are influencing the rise of “set-jetting,” especially among younger travelers.
- 75% of respondents agree that they have been inspired to travel to a specific destination by social media
- 70% of Gen Z and Millennials surveyed agree that they have been inspired to visit a destination after seeing it featured in a TV show, news source, or movie
-
46% of Gen Z and Millennials surveyed say they have been inspired to travel to a destination because of Instagram
-
From visiting top restaurants and local favorites to taking a cooking class, food has a huge impact on where people travel.
- 81% of respondents agree that trying local foods and cuisines is the part of traveling they look forward to the most
- 66% of Gen Z and Millennials surveyed agree that they get most of their eating-while-traveling inspiration from social media
-
Nearly half (47%) of Gen Z and Millennials surveyed agree that they have planned an entire trip around visiting a specific restaurant
-
Prioritizing self-care is leading to a rise in restorative vacations.
- 73% of respondents are planning vacations to better their mental, physical, and emotional health this year
-
60% of Gen Z and Millennials surveyed say they go out of their way to book hotels that offer spa and wellness services
-
Travelers want to discover hidden gems and support the local communities they visit.
- 85% of respondents want to visit a place where they can truly experience the local culture
- 78% of respondents are interested in going on vacations that support local communities in 2023
As the demand for travel continues into 2023, American Express Travel provides eligible Card Members with exceptional travel access, including 1,400+ airport lounges through its Global Lounge Collection; 7,000+ Travel Consultants; restaurant reservations through Resy and curated where-to-eat guides at Resy.com/Travel; benefits at 2,000+ hand-picked hotels around the world via Fine Hotels + Resorts® and The Hotel Collection; and more.
The full American Express Travel 2023 Global Travel Trends Report can be viewed here.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.
Key links to products, services and corporate responsibility information: personal cards, business cards and services, travel services, gift cards, prepaid cards, merchant services, Accertify, Kabbage , Resy, corporate card, business travel, diversity and inclusion, corporate responsibility and Environmental, Social, and Governance reports.
Methodology:
1The American Express 2023 Global Travel Trends Report is based on data obtained through an online poll conducted by Morning Consult between February 3rd – 11th, 2023 among a sample of 1,000 travelers from Australia, Canada, India, Japan, Mexico, UK and 2,000 travelers in the US who have a household income of at least a $70k equivalent, and who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.
2Gen Z and Millennials are defined as respondents as being born between 1981 - 2012.
Seller of Travel
American Express Travel Related Services Company, Inc. is acting solely as a sales agent for travel suppliers and is not responsible for the actions or inactions of such suppliers. Certain suppliers pay us commission and other incentives for reaching sales targets or other goals and may provide incentives to our Travel Consultants. For more information visit www.americanexpress.com/travelterms.
California CST#1022318; Washington UBI#600-469-694
Source: American Express Company
Location: New York
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005091/en/
Contact information
AMERICAN EXPRESS
Emily Vicker
Emily.Vicker@aexp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom